Anti-LILRB1 Antibody Specificity for Blocking MHC Class I Evasion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Cancer cells overexpress MHC class I to evade the immune system, necessitating a novel agent that can block the binding of LILRB1 to MHC Class I to restore immune cell function and inhibit immune evasion.
Innovation Solution
Development of anti-LILRB1 antibodies or antigen-binding fragments that bind to LILRB1, blocking its interaction with MHC Class I and inhibiting immune evasion, thereby exerting anti-cancer effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cancer cells overexpress MHC class I, then immune evasion capability is enhanced, but immune cell function is suppressed
Solution Approach 1:
The patent introduces an anti-LILRB1 antibody as an intermediary agent that binds to LILRB1 on immune cells, blocking the interaction between LILRB1 and MHC class I molecules. This mediator prevents the inhibitory signal transmission while allowing the cancer cells to maintain their MHC class I expression, thus resolving the contradiction between immune evasion and immune cell function
Solution Approach 2:
The patent changes the binding parameter of the LILRB1-MHC class I interaction by introducing a competitive inhibitor (anti-LILRB1 antibody). This parameter change blocks the inhibitory receptor-ligand interaction, thereby reversing the suppressive effect on immune cells while preserving the cancer cells' MHC class I expression profile
2Object-affected harmful factors
If LILRB1 binds to MHC Class I, then immune cell activities are inhibited, but cancer cell immune evasion is enhanced
Solution Approach 1:
The patent applies preliminary anti-action by administering anti-LILRB1 antibodies before or during cancer immune evasion processes. The antibody pre-blocks LILRB1 receptors on immune cells, preventing the inhibitory interaction with MHC class I molecules that cancer cells would otherwise exploit for immune evasion, thereby restoring immune cell activities in advance
3Object-affected harmful factors
If novel agents block LILRB1-MHC Class I interaction, then immune cell function is restored, but drug development complexity increases
Solution Approach 1:
The patent utilizes the self-service principle by leveraging the existing antibody-mediated immune recognition mechanism. The anti-LILRB1 antibody naturally binds to its target antigen LILRB1 through specific antigen-antibody interactions, utilizing the immune system's own binding specificity to achieve therapeutic effect without requiring complex synthetic mechanisms or multiple-component systems
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibodies effectively inhibit cancer cell immune evasion and exhibit anti-cancer effects by blocking the LILRB1-MHC Class I interaction, providing a therapeutic approach for cancer treatment.
Implementation Method 1
an anti-LILRB1 antibody which binds to LILRB1... having an activity to block the binding of LILRB1 to MHC Class I
Data Source
AI summary
The present invention relates to an anti-LILRB1 antibody having increased specificity for LILRB1, and to uses thereof. Specifically, provided are an anti-LILRB1 antibody or antigen-binding fragment thereof, and uses thereof in treating cancer.